A Multicenter Real-life Study of Disseminated Borreliosis Cases Occurring in Patients Receiving Anti-CD20 Treatment in France

ConditionBorrelia Infections

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age1+

SponsorUniversity Hospital, Strasbourg, France

About this trial

Clinical, biological, radiological, and pharmacological description of cases of disseminated borreliosis (Borrelia burgdorferi sl. and Borrelia miyamotoi) occurring in patients who received drug treatment based on anti-CD20 monoclonal antibodies.

Eligibility criteria

Qualifiers

Minor or adult subject

Having presented disseminated borreliosis confirmed by molecular biology (Borrelia burgdorferi sl. or Borrelia miyamotoi) within 24 months of receiving treatment with an anti-CD20 monoclonal antibody between January 1, 2010, and July 30, 2025.

Disqualifiers

None

Trial design

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Sponsors and collaborators

University Hospital, Strasbourg, France

Lead sponsor

Source ClinicalTrials.gov